Birchview Capital’s Blueprint Medicines BPMC Stock Holding History

Birchview Capital’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,700	Closed	-$346K	–	73
2025 Q2	$346K	Hold	2,700	–	–	0.34%	49
2025 Q1	$239K	Hold	2,700	–	–	0.21%	49
2024 Q4	$235K	Hold	2,700	–	–	0.19%	55
2024 Q3	$250K	Buy	+2,700	New	+$268K	0.22%	48

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Birchview Capital's BPMC Position: Q3 2025 in Review

Birchview Capital sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 2,700 shares — an estimated $346K sold.

Birchview Capital first reported a position in BPMC in Q3 2024 and held it in 4 quarters. The position peaked at $346K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Birchview Capital reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Birchview Capital sold 2,700 Blueprint Medicines shares in Q3 2025, an estimated $346K.
Birchview Capital first reported a position in Blueprint Medicines in Q3 2024 and held it in 4 quarters.
Birchview Capital's Blueprint Medicines position peaked at $346K in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Birchview Capital's 13F filing for Q3 2025, filed 13 Nov 2025.